Saal, Christoph; Becker, Axel; Krier, Mireille; Fuchss, Thomas published the artcile< Atropisomerism - A Neglected Way to Escape Out of Solubility Flatlands>, Name: 1,3-Dimethyl-4-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)-1H-pyrazole, the main research area is atropisomer aqueous solubility enantiomers; ATM; ATM-inhibitor; Ataxia-telangiectasia mutated kinase; Atropisomerism; Chirality; Crystal structure; Dissolution; Kinase inhibitor; M4076; Solubility.
Low solubility of drugs represents a major challenge during research and development. Ways to overcome this are either focused on formulation development or optimization of the mol. structure of the drug. The latter is not only governed by the constitution of the mol. but also by its stereochem. Development of enantiomers in contrast to racemic mixtures has become the state of the art over the last decades as this leads to higher potency and selectivity. Thus, enantiopure drugs require lower doses compared to their racemates. Addnl., selecting one enantiomer also leads to improved solubility of the drug compared to its racemic compound While this effect is well known for enantiomers and racemic compounds where chirality is introduced via a chiral central atom, here we describe the first case where improved solubility is realized by selecting an axially chiral atropisomer.
Journal of Pharmaceutical Sciences (Philadelphia, PA, United States) published new progress about Atropisomers. 1046832-21-6 belongs to class pyrazoles-derivatives, and the molecular formula is C11H19BN2O2, Name: 1,3-Dimethyl-4-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)-1H-pyrazole.
Referemce:
Pyrazole – Wikipedia,
Pyrazoles – an overview | ScienceDirect Topics